Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novacare (NOV) breaking out... -- Ignore unavailable to you. Want to Upgrade?

To: Todd D. Wiener who wrote (188)	1/23/1998 3:07:00 PM
From: Double Dipper	Read Replies (1) \| Respond to of 420

Todd, Thanks for the response. I have been watching for a month since your recommendations were posted. I will take advantage today. Kevin

To: Todd D. Wiener who wrote (188)	1/23/1998 8:16:00 PM
From: Machaon	Read Replies (1) \| Respond to of 420

Up until November, 1997, when NCES was still a part of NOV, the total share count was about 63 million. During November, 1997, didn't NOV split off it's PEO business as a separate stock entity, named NCES? If so, if you consider NOV and NCES still one company, the total shares outstanding, for essentially the same business, would be 88 million shares (NOV's 63 million plus NVES's 25 million). This would be a dilution of about 40%. But..... NCES WAS split off as it's own stock entity. But..... NOV still owns most of NCES. Do you happen to know the benefit to stockholders of this type of a spinoff? Could you explain to me why this spinoff would NOT be dilutive to NOV's earnings? I guess the main benefit was the $45 million taken in from the 5 million share IPO, most of which goes to NOV, right? If so, NCES's cash situation isn't going to benefit from the IPO, right? I was thinking about NOV and/or NCES as an investment and was trying to understand the value of NOV/NCES before the spinoff and after the spinoff. Thanks, Bob